metaBix Biotech

Located in Uruguay, metaBIX Biotech develops innovative biotechnology solutions that focus on monitoring and predicting the Environmental Pressure of Infection, enhancing public health safety through advanced analytics and early disease detection. Founded in 2022, metaBIX Biotech is dedicated to providing advanced biotechnology solutions for infection monitoring. The company's headquarters are based in Uruguay, focusing on supporting public health through cutting-edge technology. metaBIX Biotech’s core offering is an advanced platform that integrates hardware, biotechnology, and artificial intelligence to monitor and predict the Environmental Pressure of Infection, particularly in airborne contexts.

This technology allows for the early detection of both known and emerging diseases, providing specialized software that delivers alerts to clients up to two weeks prior to potential outbreaks. The platform primarily serves clients in healthcare, agriculture, and environmental sectors, with end users including hospitals, disease control organizations, agricultural companies, and environmental protection agencies. These solutions have been designed to enhance public safety and well-being by enabling proactive response strategies and informed decision-making. The products are marketed globally, with particular focus on regions impacted by high disease prevalence and those investing in advanced health and environmental monitoring systems.

The company generates revenue through a subscription-based model for its software platform, which includes various pricing tiers depending on the scale of implementation and the specific needs of the client. Clients typically enter into agreements that outline terms for software usage, data analytics, and ongoing support, ensuring they receive timely alerts and analysis on potential health threats. Partnerships with governmental bodies and private enterprises facilitate the dissemination of their technology, contributing to sustainable revenue streams. Flagship services include comprehensive risk assessment tools that guide users in preventive measures against airborne diseases.

While specific pricing details are proprietary, the service structure is designed to accommodate a broad spectrum of clientele, from large organizations to smaller enterprises, reflecting their commitment to accessible and impactful technology solutions. In March 2026, metaBIX Biotech raised USD 1. 3 million in venture funding co-led by Dalus Capital and EWA Capital, with participation from The Board Peru and AngelHub Ventures. The company will utilize the March 2026 funding to advance its AI‑powered biosecurity platform and accelerate commercial expansion, particularly into Brazil, while supporting global scaling initiatives.